Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Experts in Med Tech Regulation and Surgical Technologies join the Medical Sciences Division Industry Experts in Residence Scheme.

Dr Toni Day (left) and Professor Chris Cheng (right)

The Business Development Team for the Medical Sciences Division has announced the appointment of two new  experts to its Industry Experts in Residence Scheme. Dr Toni Day, Director of Quality and Regulatory Affairs at OrganOx, and Professor Chris Cheng, Consulting Professor in Vascular Surgery at Stanford and CEO of medical device company Koli Inc., became part of the scheme in December. 

The Industry Experts in Residence programme is managed by the MSD Business Development Team and Oxford University Innovation. It aims to give Oxford's research community access to world-leading expertise and advice across multiple sectors. Researchers can arrange meetings with industry experts to discuss their ideas and projects, and attend seminars give by these experts on a wide range of topics.

The scheme currently hosts experts in product design in biomedical engineering, drug discovery, and digital health, and the appointment of Dr Day and Professor Cheng has now made their expertise in Med Tech Regulation and Surgical Technologies available to researchers.

Dr Day holds a BSc Honours degree in Biochemistry and a DPhil in Neuropharmacology from the University of Oxford, and has worked for a number of start-up companies in the medical device, in vitro diagnostics and pharmaceutical arenas. She joined OrganOx Ltd in April 2011 to build the Quality Management System and the Regulatory Strategy. Toni commented: 'I am delighted to be part of the Industry Experts in Residence Scheme, and look forward to meeting researchers to discuss medical devices at all levels of the development lifecycle.' She is hosted in Oxford by the Oxford Medical CE Marking Forum (OxMCEF)

Professor Cheng is currently CEO of Koli, Inc., a medical device company developing a catheter-based solution for gallstone disease (spun out of Stanford Biodesign). He is also a Consulting Professor in Vascular Surgery at Stanford. He commented: 'I am thrilled to be at Oxford as part of the Expert in Residence program!  My colleagues in Surgery and Cardiovascular Medicine, as well as the Fellows at Exeter College, have made me feel at home since day one.  While I am here, I look forward to learning about the NHS, and am especially excited about engaging with students and faculty about academic collaborations with the medical device industry.' 

Maxine Allen, Head of Business Development and Partnering for the Medical Sciences Division, commented: 'The Industry Experts in Residence scheme is a fantastic opportunity for our researchers to develop translational strategies for their projects, and an innovative way to foster interaction between industry and academia.'

Find out more about the scheme and book an appointment with an expert 

______________________________________________________________________________________________

Upcoming workshops and talks

Professor Cheng will be running open, small group sessions about biomedical research, the medical device industry, entrepreneurship, choosing between academia and industry, and work-life balance over the coming term. These sessions will be from 2.30-4.30pm on Thurs 25 Jan, Thurs 8 Feb, Thurs 22 Feb, and Thurs 8 March in Exeter College Cohen Quad. Please send Prof. Cheng an email (christopher.cheng@exeter.ox.ac.uk) to confirm a place.  

Further workshops and events: 

Similar stories

Oxford Innovation Society celebrates pioneering biomedical research and innovation

Last month the Oxford Innovation Society (OIS) hosted an event at Pembroke College which celebrated some of the pioneering translational research and innovation coming out of the University’s Medical Sciences Division.

Oxford spinout Optellum secures $14m funding to advance pioneering AI-powered lung cancer diagnosis technology

Optellum, a University of Oxford spinout that provides a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a Series A funding round.

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from UK research institutions.

Oxford expands the Cartography collaboration with Janssen

The University of Oxford announced today that it has expanded a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation

Oxford spin-out Optellum attains CE marking for its early lung cancer diagnosis AI technology

The contribution of individual features on clinical imaging scans to the performance of the LCP-CNN cancer risk prediction model developed in Oxford was investigated.